Keytruda pembrolizumab: Additional Phase III data

Additional data from the open-label, international Phase III KEYNOTE-006 trial in 834 melanoma patients showed that first-line treatment with Keytruda given every 2 weeks and

Read the full 252 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE